Trial Profile
An Open-Label (OL) Extension Study to Assess Safety of PROCRIT (Epoetin Alfa) in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis (RA)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2016
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors Ortho Biotech
- 01 Oct 2016 New trial record